Novo Nordisk A/S (NVO)
NYSE·Healthcare·Drug Manufacturers - General
$41.15
-0.14%
Mkt Cap $176.82B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 3, 2026 | $12.13B | $12.50B | +3.10% | $0.90 | $1.00 | +11.11% | — | — |
| Q4 2025 Nov 5, 2025 | $12.37B | $11.78B | -4.76% | $0.77 | $1.02 | +32.47% | — | — |
| Q3 2025 Aug 6, 2025 | $12.30B | $12.13B | -1.39% | $0.93 | $0.97 | +4.30% | — | — |
| Q2 2025 May 7, 2025 | $11.94B | $11.49B | -3.78% | $0.92 | $0.92 | +0.00% | — | — |
| Q1 2025 Feb 5, 2025 | $11.55B | $11.86B | +2.67% | $0.88 | $0.91 | +3.41% | — | — |
| Q4 2024 Nov 6, 2024 | $10.48B | $10.68B | +1.89% | $0.87 | $0.88 | +1.38% | — | — |
| Q3 2024 Aug 7, 2024 | $10.04B | $9.80B | -2.43% | $0.70 | $0.66 | -5.87% | — | — |
| Q2 2024 May 2, 2024 | $9.07B | $9.38B | +3.45% | $0.74 | $0.82 | +10.53% | — | — |
| Q1 2024 Jan 31, 2024 | $9.15B | $9.72B | +6.18% | $0.65 | $0.71 | +9.54% | — | — |
| Q4 2023 Nov 2, 2023 | $8.17B | $8.29B | +1.41% | $0.71 | $0.71 | +0.00% | — | — |
| Q3 2023 Aug 10, 2023 | $8.21B | $7.93B | -3.33% | $0.67 | $0.63 | -5.97% | — | — |
| Q2 2023 May 4, 2023 | $7.66B | $7.78B | +1.60% | $0.63 | $0.63 | +0.00% | — | — |
| Q1 2023 Feb 1, 2023 | $6.84B | $6.95B | +1.58% | $0.41 | $0.41 | +0.00% | — | — |
| Q4 2022 Nov 2, 2022 | $5.89B | $5.97B | +1.31% | $0.42 | $0.43 | +2.38% | — | — |
| Q3 2022 Aug 3, 2022 | $5.73B | $5.79B | +1.08% | $0.44 | $0.42 | -4.55% | — | — |
| Q2 2022 Apr 29, 2022 | $5.77B | $6.25B | +8.40% | $0.43 | $0.47 | +9.30% | — | — |
| Q1 2022 Feb 2, 2022 | $5.76B | $5.84B | +1.42% | $0.35 | $0.37 | +5.71% | — | — |
| Q4 2021 Nov 3, 2021 | $5.37B | $5.56B | +3.55% | $0.40 | $0.42 | +5.00% | — | — |
| Q3 2021 Aug 4, 2021 | $5.09B | $5.27B | +3.53% | $0.38 | $0.43 | +13.16% | — | — |
| Q2 2021 May 5, 2021 | $5.12B | $5.34B | +4.33% | $0.40 | $0.44 | +10.00% | — | — |